MedPath

IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT

Phase 1
Terminated
Conditions
Acute Myeloid Leukemia
Acute Lymphocytic Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndromes
Interventions
Drug: Fludarabine
Radiation: Total Marrow Irradiation (TMI)
Registration Number
NCT03696537
Lead Sponsor
Naoyuki G. Saito, M.D., Ph.D.
Brief Summary

This is a phase I/II clinical trial on the use of total marrow irradiation (TMI) given concurrently with fludarabine, a chemotherapy drug commonly used to treat leukemia, as a myeloablative therapy for patients undergoing Allo-HSCT. TMI is a targeted technique to deliver radiation to the bone marrow while minimizing dose to other normal organs in the body. In phase I of the clinical study, the dose of radiation to the bone marrow will be incrementally increased to determine the highest tolerated TMI dose. In phase II, the effectiveness of the TMI-fludarabine conditioning regimen utilizing that dose of radiation will be studied. Acute and long-term toxicity data as well as quality of life data will also be studied.

\*Stopping criteria was met during the first dose level cohort in Phase l. The trial will not continue into Phase II as originally planned.

Detailed Description

This is a phase I/II clinical trial to determine the maximum tolerated dose (MTD) of intensity modulated radiation therapy based total marrow irradiation (TMI) concurrent with fludarabine as a myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (Allo-HSCT), as well as to determine the efficacy of the regimen in patients with high-risk and relapsed or refractory leukemia and myelodysplasia. TMI, which allows for conformal dosing of target bone marrow tissue while giving lower doses to organs at risk, is considered by many to be a superior alternative to conventional total body irradiation (TBI)

Primary Objectives:

Phase I:

Determine the MTD of TMI given concurrently with fludarabine (fixed at 150 mg/m2) as a conditioning regimen for Allo-HSCT for patients with high risk (relapsed/refractory) acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelogenous leukemia (CML).

Phase II:

Single-arm exploratory study to expand the cohort at the MTD level to estimate 1- year overall survival (OS), with the objective of increasing the OS from the historical rate of 30% (null hypothesis ) to 50% (alternate hypothesis) with 80% power and a one-sided type I error of 0.05.

Secondary Objectives

1. Describe the extramedullary toxicity and the incidence of complications, including mucositis, acute and chronic graft versus host disease (GvHD), sinusoidal obstruction syndrome (SOS), and pneumonitis.

2. Describe the time to engraftment of neutrophils and platelets

3. Describe the disease response rate at day 30 after transplantation

4. Describe the overall survival and disease-free survival

5. Describe the cumulative incidence of relapse and non-relapse mortality

6. Determine the correlation between plasma/serum markers and radiation induced acute and long term toxicities.

7. Describe the quality of life metrics of participating subjects

 * Stopping criteria was met during the first dose level cohort in Phase l. The trial will not continue into Phase II as originally planned.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
6
Inclusion Criteria

  1. Patients must be diagnosed with one of the following conditions:

    Acute Myeloid Leukemia (AML) who are not in complete remission, and who have either primary refractory or relapsed disease, and who do not have more than one of the following adverse factors:

    1. Duration of first CR < 6 months (if previously in CR)
    2. Poor risk karyotype including any of the following: complex karyotype with ≥3 clonal abnormalities, 5q-/-5, 7q-/-7, 11q23 abnormalities, inv(3q), 20q or 21q abnormalities, t(6;9), t(9;22), 17p abnormalities [or TP53 mutations] or monosomal karyotype. Molecular typing (except for TP53 mutation) will not be used for eligibility criteria determination.
    3. Circulating peripheral blood blasts at time of enrollment
    4. Karnofsky performance status <90%

    Acute Lymphocytic Leukemia (ALL) who are not in complete remission, and who have either primary refractory or relapsed disease, and who do not have more than one of the following adverse factors:

    1. First refractory relapse. Patients in second or subsequent relapse are excluded.
    2. Donor is CMV seropositive
    3. Bone marrow blasts >25% (within 30 days of admission)
    4. Age >40 years

    Myelodysplasia with a Revised International Prognostic Score (IPSS-R) of greater than 4.5 (i.e., high- or very-high risk).

    Chronic Myelogenous Leukemia (CML) in either

    1. Accelerated phase, defined by any of the following:

      • 10-19% blasts in peripheral blood white cells or bone marrow
      • Peripheral blood basophils at least 20%
      • Persistent thrombocytopenia (<100 x 109/l) unrelated to therapy, or persistent thrombocytosis (>1000 x 109/l) unresponsive to therapy
      • Increasing spleen size and increasing white blood cell (WBC) count unresponsive to therapy
      • Cytogenetic evidence of clonal evolution (i.e., the appearance of an additional genetic abnormality that was not present in the initial specimen at the time of diagnosis of chronic phase)

    2. Chronic phase provided a complete hematologic remission was not achieved by 3 months or a complete cytogenetic remission by 18 months and the patient had received at least 2 tyrosine kinase inhibitors.

  2. Patient age 18-65 years old at time of consent

  3. Availability of a consenting human leukocyte antigens(HLA) -matched donor

  4. Karnofsky Performance Status 70% or higher

  5. Required baseline laboratory values:

    1. Estimated creatinine clearance ≥ 60 ml/min
    2. Aspartate aminotransferase and alanine aminotransferease ≤ 2.5 x upper limit of normal value
    3. Bilirubin ≤ 1.5 x upper limit of normal value

  6. Required baseline cardiac function of left ventricular ejection fraction (LVEF) > 45

    • corrected

  7. Required baseline pulmonary function of lung diffusing capacity (DLCO) > 45 % predicted (corrected for hemoglobin)

  8. Patient must be capable of understanding the investigational nature of this study, potential risks and benefits of the study, and be able to provide a valid informed consent.

Read More
Exclusion Criteria
  1. Patients with ALL who are in second or subsequent relapse
  2. HIV seropositive patients.
  3. Pregnant or nursing females are excluded from this study.
  4. Prior radiation therapy
  5. Patients who have had a prior autologous or allogeneic bone marrow or stem cell transplantation
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Fludarabine + Total Marrow IrradiationFludarabine-
Fludarabine + Total Marrow IrradiationTotal Marrow Irradiation (TMI)-
Primary Outcome Measures
NameTimeMethod
Maximum-tolerated dose (MTD) of Total Marrow Irradiation (TMI) in combination with 150 mg/m2 fludarabine-Phase I onlyDay -7 of conditioning regimen through 30 days post transplant (37 days)
Overall survival (OS) rate 1 year post transplant-Phase II only1 year
Dose limiting toxicity (DLT) of Total Marrow Irradiation (TMI) in combination with 150 mg/m2 fludarabine- Phase I onlyDay -7 of conditioning regimen through 30 days post transplant (37 days)
Secondary Outcome Measures
NameTimeMethod
Incidence of sinusoidal obstruction syndrome (SOS)100 days
Incidence of pneumonitis100 days
Frequency of non hematologic toxicities100 days
Time to engraftment of neutrophilsfrom date of transplant to the first of three consecutive days after transplantation during which the absolute neutrophil count (ANC) is greater than or equal to 0.5 x 10^9/liter
Incidence of non-relapse mortality1 year
Incidence of infection100 days
Type of infections100 days
Incidence of chronic graft versus host disease (GvHD)2 years
Incidence of graft versus host disease (GvHD)100 days
Incidence of mucositis100 days
Disease response rateDay 30 after transplant (30 days)
Mean Quality of Life (QOL) as measured by Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) version 4Screening (at simulation), day +180, day +365, + 2 years from transplant (approximately 2 years)

50 item likert type scale with responses measuring from 0-4 (where 0 = not at all; 1 = a little bit; 2 = somewhat, 3 = quite; and 4 = very much) with higher scores correlating to higher QOL

Time to engraftment of plateletsfrom date of transplant until he first of seven consecutive days after transplantation during which the platelet count is greater than or equal to 20 x10^9/liters without transfusion.
Incidence of relapse mortality1 year
Disease-Free Survival2 years

Trial Locations

Locations (1)

Indiana University Melvin & Bren Simon Cancer Center

🇺🇸

Indianapolis, Indiana, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy